| Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors T Fifis, A Gamvrellis, B Crimeen-Irwin, GA Pietersz, J Li, PL Mottram, ... The Journal of Immunology 173 (5), 3148-3154, 2004 | 822 | 2004 |
| Enterococcus hirae and Barnesiella intestinihominis facilitate cyclophosphamide-induced therapeutic immunomodulatory effects R Daillère, M Vétizou, N Waldschmitt, T Yamazaki, C Isnard, ... Immunity 45 (4), 931-943, 2016 | 764 | 2016 |
| Plasmodium falciparum-infected erythrocytes modulate the maturation of dendritic cells BC Urban, DJP Ferguson, A Pain, N Willcox, M Plebanski, JM Austyn, ... Nature 400 (6739), 73-77, 1999 | 754 | 1999 |
| Induction of peptide‐specific primary cytotoxic T lymphocyte responses from human peripheral blood M Plebanski, CEM Allsopp, M Aidoo, H Reyburn, AVS Hill European journal of immunology 25 (6), 1783-1787, 1995 | 744 | 1995 |
| Pathogen recognition and development of particulate vaccines: does size matter? SD Xiang, A Scholzen, G Minigo, C David, V Apostolopoulos, PL Mottram, ... Methods 40 (1), 1-9, 2006 | 697 | 2006 |
| Two-dimensional single-cell patterning with one cell per well driven by surface acoustic waves DJ Collins, B Morahan, J Garcia-Bustos, C Doerig, M Plebanski, A Neild Nature communications 6 (1), 8686, 2015 | 530 | 2015 |
| Sex and gender differences in the outcomes of vaccination over the life course KL Flanagan, AL Fink, M Plebanski, SL Klein Annual review of cell and developmental biology 33, 577-599, 2017 | 482 | 2017 |
| Identification and characterization of three members of the human SR family of pre‐mRNA splicing factors. GR Screaton, JF Caceres, A Mayeda, MV Bell, M Plebanski, DG Jackson, ... The EMBO journal 14 (17), 4336-4349, 1995 | 366 | 1995 |
| Paclitaxel and its evolving role in the management of ovarian cancer NC Kampan, MT Madondo, OM McNally, M Quinn, M Plebanski BioMed research international 2015 (1), 413076, 2015 | 353 | 2015 |
| A CD4+ T-cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection … WHH Reece, M Pinder, PK Gothard, P Milligan, K Bojang, T Doherty, ... Nature medicine 10 (4), 406-410, 2004 | 343 | 2004 |
| Type 1 and 2 immunity following vaccination is influenced by nanoparticle size: formulation of a model vaccine for respiratory syncytial virus PL Mottram, D Leong, B Crimeen-Irwin, S Gloster, SD Xiang, J Meanger, ... Molecular pharmaceutics 4 (1), 73-84, 2007 | 340 | 2007 |
| Association of malaria parasite population structure, HLA, and immunological antagonism SC Gilbert, M Plebanski, S Gupta, J Morris, M Cox, M Aidoo, ... Science 279 (5354), 1173-1177, 1998 | 328 | 1998 |
| Vaccines that facilitate antigen entry into dendritic cells A Gamvrellis, D Leong, JC Hanley, SD Xiang, P Mottram, M Plebanski Immunology and cell biology 82 (5), 506-516, 2004 | 299 | 2004 |
| Induction of CD8+ T cells using heterologous prime‐boost immunisation strategies J Schneider, SC Gilbert, CM Hannan, P Dégano, E Prieur, EG Sheu, ... Immunological reviews 170 (1), 29-38, 1999 | 250 | 1999 |
| IMGT/HighV QUEST paradigm for T cell receptor IMGT clonotype diversity and next generation repertoire immunoprofiling S Li, MP Lefranc, JJ Miles, E Alamyar, V Giudicelli, P Duroux, JD Freeman, ... Nature communications 4 (1), 2333, 2013 | 246 | 2013 |
| Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime–boost immunisation regimes SC Gilbert, J Schneider, CM Hannan, JT Hu, M Plebanski, R Sinden, ... Vaccine 20 (7-8), 1039-1045, 2002 | 244 | 2002 |
| A protein particle vaccine containing multiple malaria epitopes SC Gilbert, M Plebanski, SJ Harris, CEM Allsopp, R Thomas, GT Layton, ... Nature biotechnology 15 (12), 1280-1284, 1997 | 234 | 1997 |
| Potent induction of focused Th1-type cellular and humoral immune responses by RTS, S/SBAS2, a recombinant Plasmodium falciparum malaria vaccine A Lalvani, P Moris, G Voss, AA Pathan, KE Kester, R Brookes, E Lee, ... The Journal of infectious diseases 180 (5), 1656-1664, 1999 | 215 | 1999 |
| Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835] V Apostolopoulos, GA Pietersz, A Tsibanis, A Tsikkinis, H Drakaki, ... Breast Cancer Research 8, 1-11, 2006 | 212 | 2006 |
| Natural regulatory T cells and persistent viral infection S Li, EJ Gowans, C Chougnet, M Plebanski, U Dittmer Journal of virology 82 (1), 21-30, 2008 | 205 | 2008 |
Sarah C GilbertProfessor of Vaccinology, Pandemic Sciences Institute, Oxford University在 ndm.ox.ac.uk 的电子邮件经过验证
